VXRT - Vaxart falls despite Motley Fool pitch

Vaxart (VXRT) may have seen over a thirteen-fold rise in share price over the past 12-month period thanks to its COVID-19 vaccine development. That meteoric rise has not discouraged the analysts to issue bullish views on the stock despite two COVID-19 vaccine candidates receiving conditional approval in the U.S.Comparing Vaxart’s share performance to that of Novavax (NVAX) which has witnessed even a sharper rise, Motley Fool author, Adria Cimino writes, “when it comes to share-price potential, Vaxart offers more room for growth.” Vaxart shares are, however, down ~1.4% in premarket trading today.The writer notes the early-stage development of Vaxart’s COVID-19 vaccine candidate but highlights its convenience in administration and logistics as reasons for it to become a potential ‘game-changer’ in the COVID-19 vaccine space subject to positive data in late-stage trials.In October, Vaxart announced the initiation of dosing in the Phase 1 trial of its oral tablet COVID-19 vaccine candidate named VXA-CoV2-1.

For further details see:

Vaxart falls despite Motley Fool pitch